Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02579382 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

A Phase 2 study of Chronic Hepatitis B, sponsored by Gilead Sciences.

Completed
Registry status
Phase 2
Development phase
192
Enrollment target
20
Study locations

NCT02579382 is a Phase 2 study of Chronic Hepatitis B that has completed, run by Gilead Sciences. The registered enrollment target is 192 participants, below the 280-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02579382, a Phase 2 study of Chronic Hepatitis B, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 2
Development phase
192 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.

Conditions Studied

Chronic Hepatitis B

Interventions

  • DRUG Placebo
  • DRUG TDF
  • DRUG Vesatolimod

Study Locations (20)

Other

  • - Kowloon
  • - Bologna
  • - Milan
  • - Pisa
  • - San Giovanni Rotondo
  • - Daegu
  • - Seoul
  • - Dalin
  • - Kaohsiung City

California

  • - Los Angeles
  • - Palo Alto
  • - San Diego
  • - San Francisco

Hawaii

  • - Honolulu

Maryland

  • - Catonsville

Massachusetts

  • - Boston

New York

  • - Flushing

Pennsylvania

  • - Philadelphia

Ontario

  • - Toronto

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2015-11-10
Est. Completion 2019-05-03
Phase Phase 2

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02579382

The ClinicalTrials.gov registry entry for NCT02579382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (31% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02579382 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Hawaii.

Frequently Asked Questions

What is clinical trial NCT02579382 about?

NCT02579382 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated". The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.

What is the current status of trial NCT02579382?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2015-11-10. Estimated completion is 2019-05-03.

What conditions does trial NCT02579382 study?

This clinical trial studies the following conditions: Chronic Hepatitis B.

What interventions are being tested in trial NCT02579382?

The interventions under investigation include: Placebo (DRUG), TDF (DRUG), Vesatolimod (DRUG).

Who is sponsoring clinical trial NCT02579382?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02579382 being conducted?

This trial has 20 study locations across California, Hawaii, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Hepatitis B

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Hepatitis B

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.